Drug
Alxn2350
Alxn2350: highest development phase Phase 1/2, developed by Alexion. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Alexion
Trials
| Drug | Phase | Indication |
|---|---|---|
| ALXN2350 NCT07218887 | Phase 1/2 | BAG3 Mutation Associated Dilated Cardiomyopathy |
Latest
No recent events.
Follow Alxn2350 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.